Skip to content

The Kanyakla Study: a Microclinic Social Network Intervention for Promoting Engagement and Retention in HIV Care

The Kanyakla Study: a Microclinic Social Network Intervention for Promoting Engagement and Retention in HIV Care

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02474992
Enrollment
304
Registered
2015-06-18
Start date
2016-01-31
Completion date
2019-06-30
Last updated
2019-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Keywords

HIV, Social network, Social support, Disclosure, Stigma, Kenya

Brief summary

The purpose of this randomized controlled trial is to compare a social network-based behavioral intervention known as microclinics to standard HIV clinical care alone in helping patients receiving HIV care on Mfangano, Remba and Ringiti Islands, Kenya remain adherent to clinic appointments. The study is designed to evaluate the effectiveness of microclinics on reducing gaps in clinical care, HIV viral load and HIV-related stigma, compared to standard HIV clinical care alone. By doing this research study, the investigators hope to learn whether microclinics are a useful social strategy for improving delivery of HIV treatment in rural Kenya.

Interventions

BEHAVIORALMicroclinic

Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.

Sponsors

Organic Health Response
CollaboratorOTHER
Microclinic International
CollaboratorOTHER
Kenya Medical Research Institute
CollaboratorOTHER
University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must be currently receiving combination antiretroviral therapy (cART) or co-trimoxozole prophylaxis from one of the eligible study clinics: * Is currently in care at study baseline, defined as having ≥1 medical care visit to receive medications (cART or prophylaxis) during the six months preceeding initiation of study enrollment, OR * Initiates pre-ART or ART care for the first time at a study clinic during the six month study recruitment period, OR * Transfers from a clinic outside the study area and receives pre-ART or ART care for the first time from a study clinic during the six month recruitment period * Participants become eligible for study inclusion on the 4th day following a missed clinic appointment, provided the patient has not transferred care to another clinic prior to the 4th day, moved outside the study area or died. Participants who miss a study visit by \>3 days but return to clinic before recruitment takes place are still eligible for study enrollment. Missed visits must have occurred within the previous 90 days at the time of eligibility assessment to meet this inclusion criteria. * Must currently reside on Mfangano, Remba or Ringiti Island. * Must be conversant with one of the commonly spoken languages within the study area (i.e. DhoLuo, Swahili or English; prior experience indicates that this represents \>99% of the adult population). * Must be ≥18 years of age as of the date of study eligibility.

Exclusion criteria

* Eligible participants who reside in the Mfangano East sub-location will be excluded from participation in this study. Many of these patients have already participated in the microclinic intervention as part of the Mfangano Island Healthy Network Impact Study. * Participants planning on moving permanently out of the study area within the next six months will be excluded. * Participants who, should they be randomized to the intervention arm, would be unwilling to participate in a microclinic will be excluded from study enrollment.

Design outcomes

Primary

MeasureTime frameDescription
Disengagement from care12 monthsIncidence of 90-day absence from care following a missed appointment

Secondary

MeasureTime frameDescription
Virologic suppression12 monthsProportion of patients who are virologically suppressed 12 months after randomization
HIV-related stigma12 monthsReduction in stigma as compared to baseline, measured by the Earnshaw HIV Stigma Framework
Re-engagement in care12 monthsIncidence of re-engagement in care following missed visit at time of study enrollment

Countries

Kenya

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026